Piyasa bakış

The Vitreoretinal Surgery Devices Market is projected to witness growth from USD 1,587 million in 2023 to USD 1,906 million by 2028, with a compound annual growth rate (CAGR) ile ilgili 3.74% tahmin dönemi boyunca (2023-2028).

Vitreoretinal surgery devices are utilized for conducting surgeries to treat various diseases, including macular degeneration, retinal detachment, uveitis, vitreous hemorrhage, macular hole and epiretinal membrane, and complications related to diabetic retinopathy.

The increasing incidence of eye disorders such as diabetic retinopathy and macular holes, along with the growing geriatric population, is driving the growth of the vitreoretinal surgery devices market during the forecast period. For instance, a research study published in May 2021 by the National Library of Medicine reported that diabetic retinopathy remained a common complication of diabetes mellitus and a leading cause of preventable blindness in the working-age adult population. The study found a prevalence of 22.27% for diabetic retinopathy, 6.17% for vision-threatening diabetes mellitus (VTDR), Ve 4.07% for clinically significant macular edema (CSME) among individuals with diabetes mellitus.

Many eye disorders are associated with aging, such as macular degeneration. With the global geriatric population on the rise, the burden of eye diseases is expected to increase, thereby fueling the growth of the vitreoretinal surgery devices market. According to the World Population Aging Highlights United Nations 2022 report, the global population aged 65 years or over reached 771 million in 2022. It is projected to reach 994 million by 2030 Ve 1.6 milyar tarafından 2050. As older adults are more susceptible to eye disorders like diabetic retinopathy and macular holes, the growing geriatric population is expected to drive the adoption of vitreoretinal surgery devices for the treatment of such conditions.

Companies in the market are actively engaged in launching new products and forming collaborations to expand their market presence. For instance, in January 2021, DORC received Health Canada approval for TissueBlue, a dye used for staining the internal limiting membrane (ILM) during vitreoretinal surgery. This approval marked the first dye authorized by Health Canada to aid in ophthalmic surgery by selectively staining the ILM. Such developments are anticipated to drive the growth of the market during the forecast period.

Pazar Segmentasyonu

Pazar çeşitli faktörlere göre bölümlere ayrılmıştır, including product type, surgery type, ve coğrafya.

Segmentation by Product Type
Perfluoro Carbon Liquids
Endoillumination Instruments
Vitreoretinal Prefilled Silicone Oil Syringes
Virectomy System
Other Product Types

Segmentation by Surgery Type
Anterior Vitreoretinal Surgery
Posterior Vitreoretinal Surgery

Coğrafyaya Göre Segmentasyon
Kuzey Amerika – Amerika Birleşik Devletleri, Kanada, Meksika
Avrupa – Birleşik Krallık, Almanya, Fransa, İtalya, ispanya, and Rest of Europe
Asia-Pacific – Çin, Japonya, Hindistan, Avustralya, Güney Kore, and Rest of Asia-Pacific
Latin Amerika – Brezilya, Arjantin, and Rest of Latin America
Middle East and Africa – GCC, Güney Afrika, and Rest of Middle East and Africa

Pars plana vitrectomy (PPV) is a widely used technique in vitreoretinal surgery that provides access to the posterior segment of the eye for the treatment of various conditions, including retinal detachments, vitreous hemorrhage, endophthalmitis, and macular holes. This procedure is performed in a controlled, closed system, ensuring precise and effective treatment. The demand for posterior vitrectomy, which involves surgical procedures to address diseases of the retina and vitreous, is driven by the high prevalence of diseases and disorders associated with the posterior segment of the eye, such as diabetic retinopathy and posterior vitreous detachment. Consequently, the growth of the posterior vitreoretinal surgery segment is expected to be significantly influenced by these factors.

For example, a study published in PLOS ONE in August 2021 highlighted that diabetic retinopathy (DR) is a common and serious complication of diabetes mellitus, characterized by damage to the blood vessels of the eyes due to high blood glucose levels. The study reported a pooled prevalence of this complication in Germany ranging from approximately 10% ile 30%, depending on the healthcare sector. Thus, the high prevalence of diabetic retinopathy is expected to drive the growth of the posterior vitreoretinal surgery segment.

Furthermore, according to an article published by WebMD in July 2021, the annual incidence of retinal detachment is estimated to be around one in 10,000 or approximately 1 in 300 over a lifetime. As a result, the posterior vitreoretinal surgery segment is projected to hold a significant share in the vitreoretinal surgery devices market. bunlara ek olarak, considering that these diseases are often associated with older adults, the rising geriatric population is expected to further contribute to the market’s growth.

Therefore, due to the high prevalence of diseases and disorders related to the posterior segment of the eye, such as diabetic retinopathy and posterior vitreous detachment, the posterior vitreoretinal surgery segment is anticipated to have a substantial market share throughout the forecast period.

North America is expected to hold a significant share in the vitreoretinal surgery devices market, with a similar trend projected for the forecast period. This is attributed to the region’s high prevalence and burden of eye diseases, as well as the increasing geriatric population. For instance, a study published by BMC Ophthalmology in May 2022 highlighted that diabetic retinopathy is considered a potentially blinding complication of diabetes mellitus, affecting approximately 28% of diabetics in the United States annually. However, routine surveillance to prevent visual impairment or blindness is not received by many Americans with diabetes mellitus. The study also revealed that undetected diabetic retinopathy may be particularly prevalent in hospital settings, with an estimated prevalence of around 44% among diabetic inpatients, of which over half were previously undiagnosed.

Dahası, the rising geriatric population in the country is expected to contribute to market growth, as vitreoretinal surgeries are commonly recommended for the treatment of eye disorders that primarily affect older individuals. According to updated data from the United Nations Population Fund dashboard in 2022, approximately 19% of Canada’s total population is 65 years or older.

Companies in the vitreoretinal surgery devices market are actively engaged in product launches, innovation, partnerships, and collaborations to expand their market presence. For instance, in March 2022, Carl Zeiss Meditec AG received 510(k) premarket approval from the United States Food and Drug Administration (FDA) for their QUATERA 700 device, which is indicated for the emulsification and removal of cataracts and anterior segment vitrectomy. Such developments are expected to drive market growth during the forecast period.

The high prevalence and burden of eye diseases, along with the increasing geriatric population, are key factors driving the growth of the vitreoretinal surgery devices market. The posterior vitreoretinal surgery segment is expected to hold a significant market share, while North America is projected to be a prominent region in terms of market size. Ongoing advancements and collaborations by companies further contribute to market expansion.

Rekabetçi Ortam

The Vitreoretinal Surgery Devices Market is characterized by a moderate level of competition, attributed to the presence of both global and regional companies. The competitive landscape of this market involves an analysis of companies based on factors such as product launches, acquisitions, collaborations, and agreements, which contribute to their market shares and reputation. Notable companies in this market include Dutch Ophthalmic Research Center International BV, Bausch & Lomb Inc., OCULUS Optikgeräte GmbH, and MedOne Surgical Inc.

Recent Industry Developments

In July 2022, Moria, a company based in France, successfully acquired AlchimiaSRL, an Italian-based company. AlchimiaSRL specializes in manufacturing devices for ophthalmic surgery and human tissue banking. This strategic acquisition will enhance Moria’s existing range of products for vitreoretinal surgery and keratoplasty.

In May 2022, D.O.R.C. Dutch Ophthalmic Research Center (International) received 510(k) premarket approval from the United States Food and Drug Administration (FDA) for their EVA NEXUS Ophthalmic Surgical System. This advanced system is specifically designed for vitreoretinal ophthalmic surgery, including the precise subretinal microinjection of gases or aqueous fluids.

Cevaplanan Anahtar Sorular

What is the anticipated size of the Vitreoretinal Surgery Devices Market?
The Vitreoretinal Surgery Devices Market is projected to reach USD 1,587 million in 2023 and is expected to grow at a CAGR of 3.74% to reach USD 1,906 million by 2028.

What is the current size of the Vitreoretinal Surgery Devices Market?
The Vitreoretinal Surgery Devices Market is expected to reach USD 1,587 million in 2023.

Who are the major players in the Vitreoretinal Surgery Devices Market?
The major companies operating in the Vitreoretinal Surgery Devices Market include Dutch Ophthalmic Research Center International BV, Bausch & Lomb, A.Ş., Alcon, Inc., Carl Zeiss, and MedOne Surgical, A.Ş..

Which region is experiencing the highest growth in the Vitreoretinal Surgery Devices Market?
Asia Pacific is projected to have the highest compound annual growth rate (CAGR) over the forecast period (2023-2028).

Which region holds the largest market share in the Vitreoretinal Surgery Devices Market?
İçinde 2023, North America accounts for the largest market share in the Vitreoretinal Surgery Devices Market.